In a report released today, Ananda Ghosh from H.C. Wainwright maintained a Buy rating on Inventiva, with a price target of $20.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ananda Ghosh has given his Buy rating due to a combination of factors related to Inventiva’s promising drug, lanifibranor. The recent presentation at the European Association for the Study of Diabetes Conference highlighted the significant role of insulin sensitivity and adipose tissue dysfunction in metabolic diseases like MASH, which aligns with lanifibranor’s mechanism of action. This drug acts as a balanced panPPAR agonist, improving insulin sensitivity and reducing inflammatory signaling, which is crucial for treating conditions not solely linked to BMI.
Furthermore, Ghosh’s analysis is reinforced by recent clinical data showing lanifibranor’s effectiveness in improving insulin sensitivity and reducing liver fat in patients with Type 2 diabetes and MASH. The drug demonstrated significant metabolic benefits, including reductions in intrahepatic triglycerides and improvements in insulin resistance across key tissues. These findings suggest that lanifibranor could be a vital therapy alongside first-line treatments, offering long-term benefits for patients with specific metabolic conditions, thus justifying the Buy rating.
In another report released on September 2, Guggenheim also reiterated a Buy rating on the stock with a $13.00 price target.